Avanos Medical (AVNS) Proxy filing summary

Executive summary

• Agreement signed for acquisition by AIP, valuing the company at approximately $1.27B, with closing expected in the second half of 2026.

• No immediate changes to roles, responsibilities, compensation, or company operations until transaction close.

• AIP, an operationally focused private equity firm, aims to support growth, innovation, and potential M&A, positioning the company for accelerated progress.

• Recent quarters showed double-digit organic revenue growth, attributed to strong execution and strategic focus on becoming a more specialized medtech company.

Voting matters and shareholder proposals

• Shareholders will receive $25 per share at close, with equity vesting accelerating upon transaction completion.

• Board determined the acquisition maximizes shareholder value and supports long-term growth.

Board of directors and corporate governance

• Board's decision to pursue the acquisition was based on strong business performance, clear strategy, and momentum toward $1B revenue by 2030.

• AIP's partnership model respects existing management and company culture, emphasizing collaboration rather than a takeover.